EGFR and osteosarcoma: In osteosarcoma (OS), ciR‐ITCH exerts oncogenic effects by activating the miR‐7/EGFR pathway, whereas in bladder cancer, it acts as a tumor suppressor through the miR‐17/miR‐224/p21/PTEN axis [38, 39].